Chowell, Diego
Yoo, Seong-Keun http://orcid.org/0000-0002-8749-7050
Valero, Cristina http://orcid.org/0000-0003-3397-2888
Pastore, Alessandro http://orcid.org/0000-0002-3621-4807
Krishna, Chirag
Lee, Mark
Hoen, Douglas
Shi, Hongyu
Kelly, Daniel W.
Patel, Neal http://orcid.org/0000-0002-4352-4723
Makarov, Vladimir
Ma, Xiaoxiao
Vuong, Lynda
Sabio, Erich Y.
Weiss, Kate
Kuo, Fengshen http://orcid.org/0000-0003-1797-2896
Lenz, Tobias L. http://orcid.org/0000-0002-7203-0044
Samstein, Robert M.
Riaz, Nadeem http://orcid.org/0000-0001-9873-5862
Adusumilli, Prasad S. http://orcid.org/0000-0002-1699-2046
Balachandran, Vinod P. http://orcid.org/0000-0002-2956-223X
Plitas, George
Ari Hakimi, A.
Abdel-Wahab, Omar http://orcid.org/0000-0002-3907-6171
Shoushtari, Alexander N.
Postow, Michael A.
Motzer, Robert J.
Ladanyi, Marc
Zehir, Ahmet http://orcid.org/0000-0001-5406-4104
Berger, Michael F. http://orcid.org/0000-0003-3882-5000
Gönen, Mithat
Morris, Luc G. T. http://orcid.org/0000-0002-4417-2280
Weinhold, Nils http://orcid.org/0000-0003-3290-6192
Chan, Timothy A. http://orcid.org/0000-0002-9265-0283
Article History
Received: 3 December 2020
Accepted: 23 August 2021
First Online: 1 November 2021
Competing interests
: T.A.C. is a co-founder of Gritstone Oncology and holds equity. T.A.C. holds equity in An2H. T.A.C. acknowledges grant funding from Bristol Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H and Eisai. T.A.C. has served as an advisor for Bristol Myers, MedImmune, Squibb, Illumina, Eisai, AstraZeneca and An2H. T.A.C., L.G.T.M. and D.C. hold ownership of intellectual property on using tumor mutational burden to predict immunotherapy response, with a pending patent, which has been licensed to PGDx. M.A.P. reports consulting fees from Bristol Myers Squibb, Merck, Array BioPharma, Novartis, Incyte, NewLink Genetics, Aduro and Eisai; honoraria from Bristol Myers Squibb and Merck; and institutional support from RGenix, Infinity, Bristol Myers Squibb, Merck, Array BioPharma, Novartis and AstraZeneca. M.L. has received advisory board compensation from Merck and Bristol Myers Squibb. The remaining authors declare no competing interests.